Physician profile
Paraag Kumar
NPI 1265751192
$1,806.97
in general payments reported to CMS, 2019-2025
18 companies · $112 in 2025
The $112 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $300 · 2023: $758 · 2024: $637 · 2025: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,507.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,507.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $509.25 | 2023-2024 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $253.30 | 2022-2024 | |
| Abbott Laboratories | $251.15 | 2023-2025 | Proclaim, Axium |
| Organon LLC | $145.73 | 2024 | |
| Exact Sciences Corporation | $112.96 | 2023-2024 | Cologuard Collection Kit |
| Novo Nordisk INC | $103.72 | 2022-2024 | Rybelsus, Ozempic |
| Pfizer INC. | $103.11 | 2022-2024 | |
| Glaxosmithkline, LLC. | $68.37 | 2023-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $52.65 | 2022-2023 | Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $36.53 | 2024 | |
| Xeris Pharmaceuticals, INC. | $34.50 | 2023 | Gvoke Hypopen |
| Array Biopharma INC | $29.75 | 2023 | Paxlovid, Prevnar 20, Comirnaty |
| Biohaven Pharmaceutical Holding Company LTD. | $23.94 | 2022 | |
| Shield Therapeutics INC | $21.78 | 2023 | Accrufer |
| Novartis Pharmaceuticals Corporation | $16.67 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.57 | 2022 | |
| Medtronic, INC. | $15.37 | 2023 | Vanta Adaptivestim |
| Amgen INC. | $11.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paraag Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.